Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06563986
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-07
Brief Title:
FTD-TPI Bevacizumab and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Single-arm Phase II Trial of TrifluridineTipiracil FTD-TPI Bevacizumab and Individualized Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STARLIGHT
Brief Summary:
Extrahepatic disease progression limits clinical efficacy of individualized radioembolization for patients with refractory metastatic colorectal cancer mCRC In the same patient population trifluridinetipiracil FTD-TPI and bevacizumab lead to disease control and overall survival benefit and may be a radiosensitizer
The purpose of this study is to determine safety tolerability and activity of individualized radioembolization with 166Holmium 166Ho-microspheres combined with FTD-TPI and bevacizumab
The purpose of this study is to determine safety tolerability and activity of individualized radioembolization with 166Holmium 166Ho-microspheres combined with FTD-TPI and bevacizumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None